{
    "clinical_study": {
        "@rank": "85774", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo was given to compare the effects"
            }, 
            {
                "arm_group_label": "Pralidoxime", 
                "arm_group_type": "Active Comparator", 
                "description": "Pralidoxime for treating organophosphorous poisoning patients"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effectiveness of Pralidoxime, a drug used for treatment of pesticide\n      poisoning (Organophosphorous poisonings)"
        }, 
        "brief_title": "Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Deaths", 
        "condition_browse": {
            "mesh_term": "Poisoning"
        }, 
        "detailed_description": {
            "textblock": "The present study was designed to critically analyze the role of pralidoxime in patients\n      with moderate to severe poisoning by dividing them into two comparable groups in all aspects\n      and using WHO recommended dose of pralidoxime (30mg/kg bolus I.V over 20 min followed by\n      8mg/kg/hr continuous infusion). This dose and continuous infusion protocol is more likely to\n      maintain adequate blood concentrations of pralidoxime throughout 24 hours and thus would\n      avoid any failures in effectiveness of pralidoxime because of inconsistent blood levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        history of alleged organophosphorus intake age > 14 years < 60 years clinical signs and\n        symptoms of organophosphorus poisoning.\n\n        Exclusion Criteria:\n\n        < 14 years or > 60 years of age known pregnancy pralidoxime administration at the\n        transferring hospital carbamate poisoning any chronic illnesses\n\n        \u2265 12 hour interval from time of poisoning to initiation of treatment pre-hospital cardiac\n        or respiratory arrest."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040350", 
            "org_study_id": "U1111-1151-9883"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "Pralidoxime"
            ], 
            "description": "Pralidoxime was compared to placebo to study the effects of the drug on mortatlity", 
            "intervention_name": "Pralidoxime", 
            "intervention_type": "Drug", 
            "other_name": "Oximes"
        }, 
        "intervention_browse": {
            "mesh_term": "Pralidoxime"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Pralidoxime, atropine, organophosphorous poisoning.", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Srinagar", 
                    "country": "India", 
                    "state": "Srinagar Kashmir", 
                    "zip": "190006"
                }, 
                "name": "Sheri kashmir insititute of medical sciences"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study Effect of WHO Recommended Dose of Pralidoxime in the Treatment of Organophosphorus Poisoning", 
        "other_outcome": {
            "measure": "duration of ICU stay", 
            "safety_issue": "No", 
            "time_frame": "upto one year"
        }, 
        "overall_official": {
            "affiliation": "SKIMS", 
            "last_name": "Showkat Gurcoo, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "mortality rate", 
            "safety_issue": "No", 
            "time_frame": "upto one year"
        }, 
        "reference": {
            "PMID": "17706760", 
            "citation": "Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16;371(9612):597-607. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040350"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheri Kashmir Institute of Medical Sciences", 
            "investigator_full_name": "Tariq Wani", 
            "investigator_title": "Registar", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "duration of ventilation", 
            "safety_issue": "No", 
            "time_frame": "upto one year"
        }, 
        "source": "Sheri Kashmir Institute of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheri Kashmir Institute of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}